{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:13:50Z","timestamp":1792725230930,"version":"4.5.0"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.blre.2019.100610","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T18:38:39Z","timestamp":1565980719000},"page":"100610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"special_numbering":"C","title":["The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS"],"prefix":"10.1016","volume":"39","author":[{"given":"Thomas","family":"McDonnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wincup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Pericleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Ripoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Delcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.100610_bb0005","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1093\/emboj\/18.19.5166","article-title":"Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure","volume":"18","author":"Bouma","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2019.100610_bb0010","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1093\/emboj\/18.22.6228","article-title":"Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome","volume":"18","author":"Schwarzenbacher","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2019.100610_bb0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.thromres.2004.07.013","article-title":"Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis","volume":"114","author":"Yasuda","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0025","first-page":"353","article-title":"The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome","volume":"62","author":"Arnout","year":"2000","journal-title":"Verh K Acad Geneeskd Belg"},{"key":"10.1016\/j.blre.2019.100610_bb0030","first-page":"3598","article-title":"\u03b22-glycoprotein I\u2013dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004"},{"key":"10.1016\/j.blre.2019.100610_bb0035","first-page":"617","article-title":"Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies","volume":"86","author":"Galli","year":"1995"},{"key":"10.1016\/j.blre.2019.100610_bb0040","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"0","key":"10.1016\/j.blre.2019.100610_bb0045","first-page":"1","article-title":"The epidemiology of antiphospholipid syndrome. A population-based study","volume":"0","author":"Duarte-Garcia","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0050","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.blre.2019.100610_bb0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/aji.12341","article-title":"Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion","volume":"73","author":"Poulton","year":"2015","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaut.2018.07.002","article-title":"Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome","volume":"93","author":"Ripoll","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/aji.12130","article-title":"Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of beta(2) glycoprotein I","volume":"70","author":"Di Simone","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0070","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/art.40416","article-title":"Antiphospholipid antibodies inhibit trophoblast toll-like receptor and inflammasome negative regulators","volume":"70","author":"Mulla","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0075","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40136","article-title":"Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation","volume":"69","author":"Abrahams","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158757","article-title":"Identification of a monoclonal antibody that attenuates antiphospholipid syndrome-related pregnancy complications and thrombosis","volume":"11","author":"Mineo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/molehr\/gaw027","article-title":"Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8","volume":"22","author":"Gysler","year":"2016","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.blre.2019.100610_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.blre.2019.100610_bb0095","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.23109","article-title":"A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","volume":"57","author":"Ruiz-Irastorza","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0100","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2019.100610_bb0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0115","article-title":"Protocol modification of Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study","volume":"24","author":"Woller","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ (Clin Res ed)"},{"key":"10.1016\/j.blre.2019.100610_bb0125","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2014.02.003","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome","volume":"13","author":"de Jesus","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.blre.2019.100610_bb0140","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0145","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb0150","first-page":"598","article-title":"Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL","volume":"46","author":"Mekinian","year":"2018","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"10.1016\/j.blre.2019.100610_bb0155","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.thromres.2004.07.017","article-title":"Beta 2 glycoprotein I--function in health and disease","volume":"114","author":"Miyakis","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0165","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0170","article-title":"The fifth domain of beta 2 glycoprotein i protects from natural IgM mediated cardiac ischaemia reperfusion injury","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb0175","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/jcp.53.11.863","article-title":"Apolipoprotein H, a new mediator in the inflammatory changes ensuring in jeopardised human myocardium","volume":"53","author":"Niessen","year":"2000","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2019.100610_bb0180","first-page":"1684","article-title":"Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome","volume":"21","author":"La Rosa","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2019.100610_bb0185","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/blood-2014-08-593624","article-title":"beta2-Glycoprotein I\/HLA class II complexes are novel autoantigens in antiphospholipid syndrome","volume":"125","author":"Tanimura","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0190","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/annrheumdis-2016-eular.5315","article-title":"AB0131 tissue beta 2 glycoprotein I in brain ischemic injury","volume":"75","author":"Artusi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2019.100610_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/ars.2014.6052","article-title":"Do beta 2-glycoprotein I disulfide bonds protect the human retina in the setting of age-related macular degeneration?","volume":"24","author":"Qi","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.blre.2019.100610_bb0200","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2249.1999.00770.x","article-title":"Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage","volume":"115","author":"Caronti","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0205","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-2249.2003.02180.x","article-title":"Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression","volume":"132","author":"Conti","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0210","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0215","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.99.17.2227","article-title":"Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression","volume":"99","author":"George","year":"1999","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2019.100610_bb0220","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/01.CIR.98.11.1108","article-title":"Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I","volume":"98","author":"George","year":"1998","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2019.100610_bb0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000028046","article-title":"Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice","volume":"67","author":"Afek","year":"1999","journal-title":"Pathobiology."},{"key":"10.1016\/j.blre.2019.100610_bb0230","doi-asserted-by":"crossref","first-page":"92652","DOI":"10.18632\/oncotarget.21536","article-title":"beta2GPI exerts an anti-obesity effect in female mice by inhibiting lipogenesis and promoting lipolysis","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.blre.2019.100610_bb0235","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1038\/s41598-017-07945-8","article-title":"Betaeta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner","volume":"7","author":"El-Assaad","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.blre.2019.100610_bb0240","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"Agar","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0245","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/art.22306","article-title":"Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43","volume":"56","author":"Ioannou","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0250","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1073\/pnas.95.26.15542","article-title":"Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI","volume":"95","author":"Iverson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100610_bb0255","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.4049\/jimmunol.169.12.7097","article-title":"Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies","volume":"169","author":"Iverson","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0260","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/jaut.2000.0427","article-title":"Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources","volume":"15","author":"Reddel","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb0265","doi-asserted-by":"crossref","first-page":"36729","DOI":"10.1074\/jbc.M504172200","article-title":"The binding site in {beta}2-glycoprotein I for ApoER2' on platelets is located in domain V","volume":"280","author":"van Lummel","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2019.100610_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2009.02.025","article-title":"Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes","volume":"9","author":"Frank","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb0275","first-page":"8","article-title":"Dimerized domain V of beta2-glycoprotein I is sufficient to upregulate procoagulant activity in PMA-treated U937 monocytes and require intact residues in two phospholipid-binding loops","volume":"6","author":"Kolyada","year":"2017","journal-title":"Antibodies (Basel, Switzerland)"},{"key":"10.1016\/j.blre.2019.100610_bb0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10409238009105472","article-title":"Zymogens and cofactors of blood coagulation","volume":"9","author":"Nemerson","year":"1980","journal-title":"CRC Critl Rev Biochem"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100610_bb0285","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0049-3848(08)70013-6","article-title":"Protein disulfide isomerase as a trigger for tissue factor-dependent fibrin generation","volume":"122","author":"Manukyan","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0290","doi-asserted-by":"crossref","first-page":"26819","DOI":"10.1039\/C8CP03234C","article-title":"Lysine residues control the conformational dynamics of beta 2-glycoprotein I","volume":"20","author":"Buchholz","year":"2018","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.blre.2019.100610_bb0295","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-02-271494","article-title":"Beta 2 glycoprotein I is a substrate of thiol oxidoreductases","volume":"116","author":"Passam","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0300","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/j.1538-7836.2010.03944.x","article-title":"Redox control of beta2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1","volume":"8","author":"Passam","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0305","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1021\/bi0603064","article-title":"Allosteric disulfide bonds","volume":"45","author":"Schmidt","year":"2006","journal-title":"Biochemistry."},{"key":"10.1016\/j.blre.2019.100610_bb0310","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.freeradbiomed.2018.03.048","article-title":"Oxidative post-translational modification of betaeta 2-glycoprotein I in the pathophysiology of the anti-phospholipid syndrome","volume":"125","author":"Weaver","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.blre.2019.100610_bb0315","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11926-010-0144-8","article-title":"Autoantibodies directed against domain I of beta2-glycoprotein I","volume":"13","author":"de Laat","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.blre.2019.100610_bb0320","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/0961203312437439","article-title":"Antibodies against domain I of beta2-glycoprotein I: the one and only?","volume":"21","author":"Pelkmans","year":"2012","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-5793(91)81065-G","article-title":"Molecular cloning and mammalian expression of human beta 2-glycoprotein I cDNA","volume":"289","author":"Kristensen","year":"1991","journal-title":"FEBS Lett"},{"key":"10.1016\/j.blre.2019.100610_bb0330","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jprot.2009.08.007","article-title":"Glycopeptide profiling of beta-2-glycoprotein I by mass spectrometry reveals attenuated sialylation in patients with antiphospholipid syndrome","volume":"73","author":"Kondo","year":"2009","journal-title":"J Proteome"},{"key":"10.1016\/j.blre.2019.100610_bb0335","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1146\/annurev.biochem.72.121801.161809","article-title":"A genetic approach to Mammalian glycan function","volume":"72","author":"Lowe","year":"2003","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.blre.2019.100610_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.12.002","article-title":"Glycans in the immune system and the altered Glycan theory of autoimmunity: a critical review","volume":"57","author":"Maverakis","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb0345","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1073\/pnas.0801340105","article-title":"Effect of glycosylation on protein folding: a close look at thermodynamic stabilization","volume":"105","author":"Shental-Bechor","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100610_bb0350","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1208\/s12248-009-9119-y","article-title":"Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII","volume":"11","author":"Kosloski","year":"2009","journal-title":"AAPS J"},{"key":"10.1016\/j.blre.2019.100610_bb0355","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2353\/ajpath.2007.070146","article-title":"Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis","volume":"171","author":"Sakai","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.blre.2019.100610_bb0360","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.24262","article-title":"beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation","volume":"60","author":"Bu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0365","first-page":"815","article-title":"The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen","volume":"2006","author":"Lopez-Lira","year":"1764","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2019.100610_bb0370","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1074\/jbc.M110176200","article-title":"Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome","volume":"277","author":"Guerin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2019.100610_bb0375","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/intimm\/12.8.1183","article-title":"Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship","volume":"12","author":"Matsuura","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0380","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/elps.1150090706","article-title":"Genetic variations of human serum beta 2-glycoprotein I demonstrated by isoelectric focusing","volume":"9","author":"Richter","year":"1988","journal-title":"Electrophoresis."},{"key":"10.1016\/j.blre.2019.100610_bb0385","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/elps.11501301185","article-title":"Genetic polymorphism of apolipoprotein H (beta 2-glycoprotein I) in African blacks from the Ivory Coast","volume":"13","author":"Cleve","year":"1992","journal-title":"Electrophoresis."},{"key":"10.1016\/j.blre.2019.100610_bb0390","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/hmg\/6.2.311","article-title":"Identification of structural mutations in the fifth domain of apolipoprotein H (2-glycoprotein I) which affect phospholipid binding","volume":"6","author":"Sanghera","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2019.100610_bb0395","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/096120339800700203","article-title":"Genetics of apolipoprotein H (beta2-glycoprotein I) and anionic phospholipid binding","volume":"7","author":"Kamboh","year":"1998","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0400","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1529-8817.2004.00097.x","volume":"68","author":"Kamboh","year":"2004","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.blre.2019.100610_bb0405","first-page":"63","article-title":"Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations","volume":"105","author":"Mehdi","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.blre.2019.100610_bb0410","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11926-000-0085-8","article-title":"Antiphospholipid antibodies and platelets","volume":"2","author":"De Jong","year":"2000","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.blre.2019.100610_bb0415","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/ATVBAHA.109.187393","article-title":"Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2)","volume":"29","author":"White-Adams","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.blre.2019.100610_bb0420","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1538-7836.2004.00712.x","article-title":"A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants","volume":"2","author":"Pengo","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0425","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-0038-1655918","article-title":"Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids","volume":"77","author":"Pengo","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0430","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1182\/blood.V94.11.3814","article-title":"Procoagulant effect of anti-beta 2-glycoprotein I antibodies with lupus anticoagulant activity","volume":"94","author":"Pengo","year":"1999","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0435","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.thromres.2006.06.003","article-title":"A functional coagulation test to identify anti-beta2-glycoprotein I dependent lupus anticoagulants","volume":"119","author":"Devreese","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0440","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1538-7836.2008.02979.x","article-title":"Protein C supports platelet binding and activation under flow: role of glycoprotein Ib and apolipoprotein E receptor 2","volume":"6","author":"White","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0445","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2249.2000.01248.x","article-title":"Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome","volume":"120","author":"Hanly","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0450","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1055\/s-2007-994958","article-title":"The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinolytic systems by monoclonal anticardiolipin antibodies","volume":"25","author":"Ieko","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0455","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/jcp.46.10.908","article-title":"Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro","volume":"46","author":"Keeling","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2019.100610_bb0460","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clim.2004.02.014","article-title":"Beta-2 glycoprotein I and its role in antiphospholipid syndrome-lessons from knockout mice","volume":"112","author":"Miyakis","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0465","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/jcp.46.10.908","article-title":"Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro","volume":"46","author":"Keeling","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.blre.2019.100610_bb0470","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0021-9150(87)90110-9","article-title":"Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation","volume":"63","author":"Nimpf","year":"1987","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.blre.2019.100610_bb0475","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/art.23387","article-title":"Beta2-glycoprotein I protects thrombin from inhibition by heparin cofactor II: potentiation of this effect in the presence of anti-beta2-glycoprotein I autoantibodies","volume":"58","author":"Rahgozar","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0480","first-page":"3939","article-title":"\u03b22-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped \u03b22-glycoprotein I","volume":"101","author":"Shi","year":"2004"},{"key":"10.1016\/j.blre.2019.100610_bb0485","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0038-1649577","article-title":"Anticardiolipin antibodies block the inhibition by beta 2-glycoprotein I of the factor Xa generating activity of platelets","volume":"70","author":"Shi","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0490","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.5551\/jat.34488","article-title":"Circulating immune complexes of IgA bound to beta 2 glycoprotein are strongly associated with the occurrence of acute thrombotic events","volume":"23","author":"Mart\u00ednez-Flores","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.blre.2019.100610_bb0495","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1161\/CIRCULATIONAHA.116.025992","article-title":"beta2-glycoprotein I\/IgA immune complexes: a marker to predict thrombosis after renal transplantation in patients with antiphospholipid antibodies","volume":"135","author":"Serrano","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.blre.2019.100610_bb0500","article-title":"Presence of immune complexes of IgG\/IgM bound to B2-glycoprotein I is associated with non-criteria clinical manifestations in patients with antiphospholipid syndrome","volume":"9","author":"P\u00e9rez","year":"2018"},{"key":"10.1016\/j.blre.2019.100610_bb0505","first-page":"71","article-title":"Interaction between the coagulation and complement system","volume":"632","author":"Amara","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.blre.2019.100610_bb0510","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12959-016-0115-z","article-title":"Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome","volume":"14","author":"El-Assaad","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.blre.2019.100610_bb0515","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"beta-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0520","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2010-12-325951","article-title":"beta(2)-glycoprotein I: a novel component of innate immunity","volume":"117","author":"Agar","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0525","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fimmu.2018.01388","article-title":"Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.blre.2019.100610_bb0530","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0535","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100610_bb0540","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4049\/jimmunol.174.1.485","article-title":"TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss","volume":"174","author":"Berman","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0545","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100610_bb0550","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2019.100610_bb0555","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/molehr\/gal048","article-title":"Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome","volume":"12","author":"Francis","year":"2006","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.blre.2019.100610_bb0560","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta 2-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0565","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2019.100610_bb0570","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and Renal Transplantation in a Patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2019.100610_bb0575","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.autrev.2019.03.015","article-title":"Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab","volume":"18","author":"Ruffatti","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.blre.2019.100610_bb0580","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0585","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/rheumatology\/key228","article-title":"Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review","volume":"57","author":"Guillot","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2019.100610_bb0590","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.2015.0197","article-title":"The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome","volume":"33","author":"Erkan","year":"2016","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.blre.2019.100610_bb0600","doi-asserted-by":"crossref","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.blre.2019.100610_bb0605","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0610","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fimmu.2015.00215","article-title":"Complement-coagulation cross-talk: a potential mediator of the physiological activation of complement by low pH","volume":"6","author":"Kenawy","year":"2015","journal-title":"Front Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100610_bb0615","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.thromres.2014.03.014","article-title":"Crosstalk between the coagulation and complement systems in sepsis","volume":"133","author":"Lupu","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0620","article-title":"Crosstalk of the complement and coagulation system","volume":"22","author":"Umme-Amara","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.blre.2019.100610_bb0625","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3389\/fimmu.2018.02244","article-title":"Antiphospholipid antibodies to domain I of beta-2-glycoprotein I show different subclass predominance in comparison to antibodies to whole beta-2-glycoprotein I","volume":"9","author":"McDonnell","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0630","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/08916939908994054","article-title":"Anti-beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients","volume":"31","author":"Guerin","year":"1999","journal-title":"Autoimmunity."},{"key":"10.1016\/j.blre.2019.100610_bb0635","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2249.1994.tb06529.x","article-title":"IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients","volume":"95","author":"Arvieux","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0640","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/40.9.1026","article-title":"IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations","volume":"40","author":"Samarkos","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2019.100610_bb0645","first-page":"439","article-title":"Activation of platelets by modified C-reactive protein","volume":"45","author":"Fiedel","year":"1982","journal-title":"Immunology."},{"key":"10.1016\/j.blre.2019.100610_bb0650","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-015-0077-0","article-title":"C-reactive protein enhances activation of coagulation system and inflammatory response through dissociating into monomeric form in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"16","author":"Xu","year":"2015","journal-title":"BMC Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0655","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4330\/wjc.v2.i11.365","article-title":"Linking inflammation and thrombosis: role of C-reactive protein","volume":"2","author":"Fay","year":"2010","journal-title":"World J Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100610_bb0660","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.thromres.2012.08.269","article-title":"Conformation of beta2glycoprotein I and its effect on coagulation","volume":"130","author":"Ninivaggi","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0665","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1172\/JCI3772","article-title":"beta2-glycoprotein-I (apolipoprotein H) and beta2-glycoprotein-I-phospholipid complex harbor a recognition site for the endocytic receptor megalin","volume":"102","author":"Moestrup","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2019.100610_bb0670","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1074\/jbc.M114.619817","article-title":"beta2-Glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies","volume":"290","author":"Salem","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2019.100610_bb0675","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/08916934.2013.783025","article-title":"Antiphospholipid antibodies mediate autoimmunity against dying cells","volume":"46","author":"Andreoli","year":"2013","journal-title":"Autoimmunity."},{"key":"10.1016\/j.blre.2019.100610_bb0680","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.molimm.2011.06.250","article-title":"Beta 2 glycoprotein 1 (beta 2GPI), the major target in anti phospholipid syndrome (APS), regulates complement activation on the level of C3\/C3b","volume":"48","author":"Skerka","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0690","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/1529-0131(199802)41:2<205::AID-ART4>3.0.CO;2-0","article-title":"Apoptotic cell clearance in systemic lupus erythematosus - I. Opsonization by antiphospholipid antibodies","volume":"41","author":"Manfredi","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0695","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/1529-0131(199802)41:2<215::AID-ART5>3.0.CO;2-X","article-title":"Apoptotic cell clearance in systemic lupus erythematosus - II. Role of beta(2)-glycoprotein I","volume":"41","author":"Manfredi","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0700","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jlb.66.2.345","article-title":"Autoantibody opsonization of apoptotic cells facilitates antigen presentation by dendritic cells: implications for autoimmunity establishment in systemic lupus erythematosus","volume":"66","author":"Rovere","year":"1999","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.blre.2019.100610_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186513","article-title":"Oxidation of \u03b22-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome","volume":"12","author":"Raimondo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb0710","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaut.2007.07.003","article-title":"Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome","volume":"29","author":"Kajiwara","year":"2007","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb0715","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.blre.2019.100610_bb0720","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3389\/fimmu.2017.01907","article-title":"Antigen presentation by vascular cells","volume":"8","author":"Pober","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0725","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2004-05-1708","article-title":"Annexin A2 mediates endothelial cell activation by antiphospholipid\/anti-beta(2) glycoprotein I antibodies","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0730","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2014.03.001","article-title":"beta2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis","volume":"55","author":"Raschi","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb0735","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0961203314536479","article-title":"Toll-like receptor 4 and beta2 glycoprotein I interaction on endothelial cells","volume":"23","author":"Borghi","year":"2014","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0740","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2017-11-814681","article-title":"Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium","volume":"131","author":"Sacharidou","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0745","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.4049\/jimmunol.1600305","article-title":"beta2 glycoprotein i recognition drives Th1 inflammation in atherosclerotic plaques of patients with primary antiphospholipid syndrome","volume":"198","author":"Benagiano","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb0750","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.209536","article-title":"Interleukin-17\/Interleukin-21 and Interferon-g producing T cells specific for beta2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome","author":"Benagiano","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2019.100610_bb0755","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood.V98.6.1889","article-title":"Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site","volume":"98","author":"Arai","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0760","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-016-1018-x","article-title":"Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers","volume":"18","author":"Roggenbuck","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2019.100610_bb0765","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.33349","article-title":"International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies","volume":"64","author":"Lakos","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0770","first-page":"809","article-title":"Antibodies tSoLAA","volume":"16","author":"Devreese","year":"2018","journal-title":"Lab Criteria Antiphospholipid Syndr: Commun SSC ISTH"},{"key":"10.1016\/j.blre.2019.100610_bb0775","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13317-018-0106-0","article-title":"Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases","volume":"9","author":"Nalli","year":"2018","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.blre.2019.100610_bb0780","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0961203316641772","article-title":"Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools","volume":"25","author":"Meroni","year":"2016","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0785","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"de Laat","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0790","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2005-05-1943","article-title":"Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change","volume":"107","author":"de Laat","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0795","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study","volume":"7","author":"de Laat","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0800","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2006-07-030148","article-title":"Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5","volume":"109","author":"de Laat","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0805","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of \u00df2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0810","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.thromres.2010.05.018","article-title":"Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA)","volume":"126","author":"Pengo","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100610_bb0815","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s10067-012-2019-z","article-title":"Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjogren's syndrome","volume":"31","author":"Pasoto","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.blre.2019.100610_bb0820","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1160\/TH10-09-0606","article-title":"Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients","volume":"105","author":"Devreese","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0825","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1538-7836.2010.03933.x","article-title":"Plasma and IgGs from patients with lupus anticoagulant induce tissue factor in monocytes: a possible risk factor for thrombosis","volume":"8","author":"Le","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0830","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1538-7836.2005.01394.x","article-title":"The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant","volume":"3","author":"Zoghlami-Rintelen","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0835","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb0840","first-page":"1710","article-title":"Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis","volume":"24","author":"Swadzba","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2019.100610_bb0845","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1055\/s-0038-1657667","article-title":"Relationship of lupus anticoagulant, anticardiolipin, anti-beta2-GPI and anti-prothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome","volume":"78","author":"D'Angelo","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0850","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/ard.2003.006163","article-title":"Seronegative antiphospholipid syndrome","volume":"62","author":"Hughes","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2019.100610_bb0855","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0961203319826358","article-title":"'Seronegative antiphospholipid syndrome': an update","volume":"28","author":"Hughes","year":"2019","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0860","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.autrev.2014.05.001","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends","volume":"13","author":"Bertolaccini","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb0865","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1177\/0961203316640366","article-title":"Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome","volume":"25","author":"Mahler","year":"2016","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0870","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1603936","article-title":"Prevalence and thrombotic risk assessment of anti-beta2 glycoprotein I domain I antibodies: a systematic review","volume":"44","author":"Radin","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0875","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: anti-beta2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome","volume":"90","author":"Chighizola","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb0880","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2018.198119","article-title":"New insight into antiphospholipid syndrome: antibodies to beta2glycoprotein I-domain 5 fail to induce thrombi in rats","volume":"104","author":"Durigutto","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2019.100610_bb0885","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2010.137281","article-title":"Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4\/5: might it be the reason for their 'innocent' profile?","volume":"70","author":"Andreoli","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2019.100610_bb0890","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/art.39187","article-title":"Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein i domain 1 and domain 4\/5: ratio of anti-domain 1 to anti-domain 4\/5 as a useful new biomarker for antiphospholipid syndrome","volume":"67","author":"Andreoli","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0895","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1055\/s-0038-1649940","article-title":"Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome","volume":"74","author":"Pierangeli","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0900","article-title":"The prevalence and clinical significance of IgA antiphospholipid antibodies (aPL)","volume":"106","author":"Shen","year":"2005"},{"key":"10.1016\/j.blre.2019.100610_bb0905","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11926-013-0343-1","article-title":"Clinical significance of IgA anti-cardiolipin and IgA anti-beta2glycoprotein I antibodies","volume":"15","author":"Andreoli","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.blre.2019.100610_bb0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156407","article-title":"Measuring IgA anti-beta2-glycoprotein I and IgG\/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome","volume":"11","author":"Pericleous","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb0915","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1002\/art.38131","article-title":"Value of isolated IgA anti-beta2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome","volume":"65","author":"Murthy","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb0920","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/annrheumdis-2014-206483","article-title":"Antibodies to domain I of beta-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome","volume":"74","author":"Cousins","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.blre.2019.100610_bb0925","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cca.2011.09.048","article-title":"Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies","volume":"413","author":"Pierangeli","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.blre.2019.100610_bb0930","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0032-1313564","article-title":"Current international initiatives in antiphospholipid antibody testing","volume":"38","author":"Willis","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0935","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1055\/s-0033-1364207","article-title":"Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives","volume":"40","author":"Willis","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0940","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1177\/0961203314544535","article-title":"International standards for IgG and IgM anti-beta2glycoprotein antibody measurement","volume":"23","author":"Willis","year":"2014","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0945","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/ajcp\/aqw065","article-title":"Performance characteristics of commercial immunoassays for the detection of IgG and IgM antibodies to beta2 glycoprotein I and an initial assessment of newly developed reference materials for assay calibration","volume":"145","author":"Willis","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2019.100610_bb0950","doi-asserted-by":"crossref","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0955","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0961203309360544","article-title":"Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome","volume":"19","author":"Ioannou","year":"2010","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb0960","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0965","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0037-1601329","article-title":"The significance of antibodies against domain I of beta-2 glycoprotein I in antiphospholipid syndrome","volume":"44","author":"Kelchtermans","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0970","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jth.12865","article-title":"Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk","volume":"13","author":"Pengo","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0975","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/jth.13389","article-title":"Role of anti-domain 1-beta2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome","volume":"14","author":"De Craemer","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb0980","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.02.019","article-title":"Clinical significance of anti-domain 1 beta2-glycoprotein I antibodies in antiphospholipid syndrome","volume":"153","author":"Iwaniec","year":"2017","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.blre.2019.100610_bb0985","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1603936","article-title":"Prevalence and thrombotic risk assessment of anti-beta2 glycoprotein I domain I antibodies: a systematic review","volume":"44","author":"Radin","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100610_bb0990","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.autrev.2018.06.011","article-title":"The clinical value of assays detecting antibodies against domain I of \u03b22-glycoprotein I in the antiphospholipid syndrome","volume":"17","author":"Yin","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb0995","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0961203316660203","article-title":"Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study","volume":"26","author":"Amengual","year":"2017","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb1000","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/art.33340","article-title":"Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events","volume":"64","author":"Otomo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.blre.2019.100610_bb1005","article-title":"THU0400 response to eculizumab in the antiphospholipid antibody syndrome","volume":"74","author":"Zapantis","year":"2015"},{"key":"10.1016\/j.blre.2019.100610_bb1010","first-page":"2774","article-title":"\u03b22-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011"},{"key":"10.1016\/j.blre.2019.100610_bb1015","first-page":"2080","article-title":"Identification of the binding site for fondaparinux on Beta2-glycoprotein I","volume":"2013","author":"Kolyada","year":"1834","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2019.100610_bb1020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015345","article-title":"A novel dimeric inhibitor targeting beta2GPI in Beta2GPI\/antibody complexes implicated in antiphospholipid syndrome","volume":"5","author":"Kolyada","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb1025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.str.2009.12.013","article-title":"Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids","volume":"18","author":"Lee","year":"2010","journal-title":"Struct (Lond Engl: 1993)"},{"key":"10.1016\/j.blre.2019.100610_bb1030","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/febs.13185","article-title":"A1-A1 mutant with improved binding and inhibition of beta2GPI\/antibody complexes in antiphospholipid syndrome","volume":"282","author":"Kolyada","year":"2015","journal-title":"FEBS J"},{"key":"10.1016\/j.blre.2019.100610_bb1035","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood-2013-08-520882","article-title":"Inhibition of thrombotic properties of persistent autoimmune anti-\u03b22GPI antibodies in the mouse model of antiphospholipid syndrome","volume":"123","author":"Kolyada","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb1040","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jth.13314","article-title":"Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome","volume":"14","author":"Kolyada","year":"2016","journal-title":"J Thromb Haemost: JTH"},{"key":"10.1016\/j.blre.2019.100610_bb1045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaut.2004.01.002","article-title":"A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo","volume":"22","author":"Pierangeli","year":"2004","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb1050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1191\/0961203306lu2315oa","article-title":"A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice","volume":"15","author":"Ostertag","year":"2006","journal-title":"Lupus."},{"key":"10.1016\/j.blre.2019.100610_bb1055","doi-asserted-by":"crossref","first-page":"J209","DOI":"10.1016\/j.jaut.2011.11.009","article-title":"Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss","volume":"38","author":"de la Torre","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb1060","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/rheumatology\/keu360","article-title":"Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis","volume":"54","author":"Pericleous","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.blre.2019.100610_bb1065","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.235","article-title":"Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia\/reoxygenation injury model via p38 MAPK","volume":"8","author":"Bourke","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.blre.2019.100610_bb1070","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3389\/fimmu.2018.02413","article-title":"PEGylated domain I of beta-2-glycoprotein I inhibits the binding, coagulopathic, and thrombogenic properties of IgG from patients with the antiphospholipid syndrome","volume":"9","author":"McDonnell","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2019.100610_bb1075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2019.02.002","article-title":"Oral administration of domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome","volume":"99","author":"Shemer","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb1080","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"Agostinis","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2019.100610_bb1085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.07.003","article-title":"Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?","volume":"75","author":"Meroni","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb1090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.blre.2019.100610_bb1095","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2016.04.008","article-title":"Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome","volume":"75","author":"Bertolaccini","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.blre.2019.100610_bb1100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212614","article-title":"Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction","volume":"14","author":"Miranda","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb1105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206814","article-title":"Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome","volume":"13","author":"Urbanski","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100610_bb1110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/kex378","article-title":"The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies","volume":"57","author":"Schreiber","year":"2018","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.blre.2019.100610_bb1115","first-page":"639","article-title":"Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study","volume":"118","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100610_bb1120","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome","volume":"14","author":"Belizna","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.blre.2019.100610_bb1125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19300268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:22:31Z","timestamp":1759436551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19300268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":225,"alternative-id":["S0268960X19300268"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100610","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100610"}}